Selecta Biosciences Inc. (SELB) Receives $30.00 Average Price Target from Analysts

Selecta Biosciences Inc. (NASDAQ:SELB) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $30.00.

A number of equities analysts recently commented on SELB shares. Zacks Investment Research cut Selecta Biosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 21st. BidaskClub upgraded Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Canaccord Genuity reiterated a “buy” rating and set a $30.00 price target on shares of Selecta Biosciences in a report on Thursday, January 18th. Mizuho started coverage on Selecta Biosciences in a report on Monday, February 26th. They set a “buy” rating and a $30.00 price target for the company. Finally, ValuEngine cut Selecta Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.

Selecta Biosciences stock traded up $0.25 during midday trading on Friday, reaching $11.96. 183,900 shares of the company’s stock were exchanged, compared to its average volume of 298,823. Selecta Biosciences has a 52 week low of $11.54 and a 52 week high of $11.65. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.20 and a current ratio of 7.20. The stock has a market capitalization of $257.25 million, a P/E ratio of -3.74 and a beta of -3.65.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.11). Selecta Biosciences had a negative return on equity of 111.69% and a negative net margin of 31,556.04%. research analysts forecast that Selecta Biosciences will post -3.29 earnings per share for the current year.

Several large investors have recently modified their holdings of SELB. Bank of New York Mellon Corp boosted its holdings in shares of Selecta Biosciences by 26.6% during the third quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock worth $748,000 after acquiring an additional 8,620 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Selecta Biosciences by 50.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock worth $541,000 after acquiring an additional 9,900 shares during the period. Wasatch Advisors Inc. boosted its holdings in shares of Selecta Biosciences by 100.6% during the fourth quarter. Wasatch Advisors Inc. now owns 246,618 shares of the company’s stock worth $2,419,000 after acquiring an additional 123,695 shares during the period. SG Americas Securities LLC bought a new stake in shares of Selecta Biosciences in the fourth quarter valued at approximately $145,000. Finally, Alps Advisors Inc. bought a new stake in shares of Selecta Biosciences in the fourth quarter valued at approximately $243,000. Institutional investors own 48.24% of the company’s stock.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit